Forus 融资 1.5 亿美元，估值翻三倍，将 AI Agent 带入每一家医疗机构
Forus Triples Raises $150M to Put AI Agents in Every Medical Practice
你需要了解的内容
Forus 是一个 AI 驱动的网络，连接医生、零售药房和专科药房、商业支付方以及生物制药制造商，宣布以 30 亿美元估值完成 1.5 亿美元 C 轮融资。
本轮融资使公司在 B 轮融资仅数月后估值翻了三倍，累计股权融资超过 3 亿美元。
本轮由种子轮投资方 Bain Capital Ventures 领投，这轮内部轮中现有机构投资方 100% 追加投资，包括 Thrive Capital、General Catalyst、Accel、Redpoint、BoxGroup、Pear VC、Avra、Human Capital、Neo、Vast Ventures 和 SV Angel。
直接针对专科医学中的一个核心断点：每三名被开具高成本或复杂疾病疗法的患者中，就有一人从未接受其初始剂量，而那些确实接受初始剂量的患者，通常也会因事前授权（PA）和财务审核障碍而等待数周或数月。
为每一张处方分配一个 AI Agent
Forus 由 Sahir Jaggi 于 2023 年创立，提供的平台充当智能连接组织，将开方医生、专科药房、支付方和生物制药商业团队连接起来。该平台向医疗服务提供者和患者免费提供，为每一张符合条件的处方提供一个专用的自主 AI agent，并直接嵌入临床电子工作流程。
每个 agent 像自动化个案管理员一样运作，基于患者的医疗记录、保险覆盖规则和财务援助选项进行推理，以协调完成路径：
加速事前授权：
通过将临床适应证与动态支付方政策交叉比对，审批时间从数周缩短至 48 小时以内。
财务援助与 Hub 自动化：
实时将符合条件的患者与制造商共付卡、基金会赠款和零美元获取项目连接起来。
专科药房协调：
将处方直接路由至网络内批准且库存已验证的配药药房，使患者能在一到两周内开始复杂疗法，而不是数月。
专科领域的快速采用与全国覆盖
该平台已建立广泛的全国影响力，美国全部 50 个州的医疗服务提供者都在使用 Forus 治疗患者，这些患者居住在美国 85% 的住宅 ZIP 编码地区。
在其最初推出的专科——风湿病学中，美国超过三分之一的提供者已采用该网络，并且两位数的提供者采用率正在若干后续专科中扩展。
除了减轻提供者工作流程负担外，该网络还在整个药品生命周期中产生可操作的可见性。通过捕捉处方在何处停滞以及疗法在真实世界环境中的表现，Forus 目前与全球前 15 大生物制药公司中的 9 家合作，以简化商业产品上市并优化临床试验方案设计。
“我们正在将 Forus 平台部署到全国每一家医生诊所，以便每一种疾病都能用科学所能提供的最佳药物来治疗，”Forus 首席执行官兼创始人 Sahir Jaggi 表示。“医学进步的速度比历史上任何时候都快，这让确保这些进步惠及它们本该惠及的人群变得更加紧迫。我们正在构建 Forus，以确保科学成为医学的唯一限制。”
What You Should Know Forus, the AI-powered network connecting physicians, retail and specialty pharmacies, commercial payers, and biopharma manufacturers, announced a $150M Series C financing round at a $3B valuation.
The round triples the company’s valuation just months following its Series B round, lifting cumulative equity financing past $300M.
Led by seed-stage backer
Bain Capital Ventures, the insider round featured 100% reinvestment from existing institutional backers, including Thrive Capital General Catalyst Accel Redpoint BoxGroup Pear VC Avra Human Capital Neo Vast Ventures, and SV Angel Directly targets a core breakdown in specialty medicine: one in three patients prescribed therapies for high-cost or complex conditions never receives their initial dose, while those who do regularly wait weeks or months due to prior authorization (PA) and financial clearance hurdles.
Assigning an AI Agent to Every Prescription
Founded in 2023 by Sahir Jaggi, Forus provides a platform that functions as an intelligent connective tissue linking prescribing physicians, specialty pharmacies, payers, and biopharma commercial teams. Offered free to providers and patients, the platform gives every qualifying prescription a dedicated, autonomous AI agent embedded directly into clinical electronic workflows.
Operating like an automated case manager, each agent reasons across a patient’s medical records, insurance coverage rules, and financial assistance options to orchestrate the fulfillment path:
Accelerated Prior Authorization:
By cross-referencing clinical indications with dynamic payer policies, approval times shrink from several weeks to under 48 hours.
Financial Assistance & Hub Automation:
Connects eligible patients with manufacturer copay cards, foundation grants, and zero-dollar access programs in real time.
Specialty Pharmacy Orchestration:
Routes scripts directly to network-approved dispensing pharmacies with verified stock, enabling patients to start complex therapies within one to two weeks rather than months.
Rapid Specialty Adoption and National Footprint
The platform has established a widespread national presence, with healthcare providers across all 50 U.S. states using Forus to treat patients residing in 85% of U.S. residential ZIP codes.
In its initial rollout specialty of rheumatology, more than one-third of all U.S. providers have adopted the network, with double-digit provider adoption scaling across several follow-on specialties.
Beyond provider workflow relief, the network generates actionable visibility across the pharmaceutical lifecycle. By capturing where prescriptions stall and how therapies perform in real-world settings, Forus now collaborates with 9 of the top 15 global biopharma companies to streamline commercial product launches and optimize clinical trial protocol design.
“We are putting the Forus platform in every doctor’s office in the country, so every disease is treated with the best medicine science can offer,” said Sahir Jaggi, CEO and founder of Forus. “Medicine is advancing faster than at any point in history, increasing the urgency to make sure those advances reach the people they’re meant for. We are building Forus to ensure science is the only limit to medicine.” Reader Interactions